
Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
LATEST POSTS
- 1
Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel - 2
She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present? - 3
Iran executes two men who tried storming military facility during January protest crackdown - 4
The most effective method to Boost Eco-friendliness in Your Volvo XC40 - 5
Windows to the Previous: An Excursion Through the World's Notable Engineering
New movies to watch this weekend: See 'Wake Up Dead Man: A Knives Out Mystery' in theaters, rent 'Bugonia,' stream 'Caught Stealing' on Netflix
Major Scottish gangland figure Steven Lyons arrested in Bali
Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
5 Chiefs That Changed Our Opinion on Film
Online business Stages for Little Retailers
'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
The 10 Most Famous Style Minutes on Honorary pathway
AstraZeneca to acquire Modella AI to speed oncology drug research












